Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity

doi:10.1038/clpt.2013.219

Comment

. 2014 Mar;95(3):253.

doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5.

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity

B C Carleton¹, C J Ross², A P Bhavsar³, U Amstutz¹, K Pussegoda³, H Visscher³, J W Lee⁴, B Brooks⁵, S R Rassekh⁶, M-P Dubé⁷, M R Hayden⁴

Affiliations

¹ 1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Department of Pediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada.
² 1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Department of Pediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [4] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
³ Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
⁴ 1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
⁵ Audiology and Speech Pathology Department, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
⁶ 1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
⁷ Montreal Heart Institute Research Centre and Université de Montreal, Montreal, Quebec, Canada.

PMID: 24193170
DOI: 10.1038/clpt.2013.219

Comment

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity

B C Carleton et al. Clin Pharmacol Ther. 2014 Mar.

. 2014 Mar;95(3):253.

doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5.

Authors

B C Carleton¹, C J Ross², A P Bhavsar³, U Amstutz¹, K Pussegoda³, H Visscher³, J W Lee⁴, B Brooks⁵, S R Rassekh⁶, M-P Dubé⁷, M R Hayden⁴

Affiliations

¹ 1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Department of Pediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada.
² 1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Department of Pediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [4] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
³ Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
⁴ 1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
⁵ Audiology and Speech Pathology Department, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
⁶ 1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
⁷ Montreal Heart Institute Research Centre and Université de Montreal, Montreal, Quebec, Canada.

PMID: 24193170
DOI: 10.1038/clpt.2013.219

No abstract available

PubMed Disclaimer

Comment on

The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.
Yang JJ, Lim JY, Huang J, Bass J, Wu J, Wang C, Fang J, Stewart E, Harstead EH, E S, Robinson GW, Evans WE, Pappo A, Zuo J, Relling MV, Onar-Thomas A, Gajjar A, Stewart CF. Yang JJ, et al. Clin Pharmacol Ther. 2013 Aug;94(2):252-9. doi: 10.1038/clpt.2013.121. Epub 2013 Jun 11. Clin Pharmacol Ther. 2013. PMID: 23820299 Free PMC article.

Cited by

Cochlear protection against cisplatin by viral transfection of X-linked inhibitor of apoptosis protein across round window membrane.
Jie H, Tao S, Liu L, Xia L, Charko A, Yu Z, Bance M, Yin S, Robertson GS, Wang J. Jie H, et al. Gene Ther. 2015 Jul;22(7):546-52. doi: 10.1038/gt.2015.22. Epub 2015 Mar 26. Gene Ther. 2015. PMID: 25809464
Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.
Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH. Maagdenberg H, et al. Paediatr Drugs. 2016 Aug;18(4):251-60. doi: 10.1007/s40272-016-0176-2. Paediatr Drugs. 2016. PMID: 27142473 Free PMC article. Review.
Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment.
Morton LM, Kerns SL, Dolan ME. Morton LM, et al. Am Soc Clin Oncol Educ Book. 2018 May 23;38(38):775-786. doi: 10.1200/EDBK_201391. Am Soc Clin Oncol Educ Book. 2018. PMID: 30231410 Free PMC article. Review.
Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
Bhavsar AP, Gunaretnam EP, Li Y, Hasbullah JS, Carleton BC, Ross CJ. Bhavsar AP, et al. PLoS One. 2017 Apr 13;12(4):e0175711. doi: 10.1371/journal.pone.0175711. eCollection 2017. PLoS One. 2017. PMID: 28406961 Free PMC article.
Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study.
Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, de Vries A, Kuehni CE, Garrè ML, Kepak T, Kruseova J, Winther JF, Kremer LC, van Dulmen-den Broeder E, Tissing WJ, Rechnitzer C, Kenborg L, Hasle H, Grabow D, Parfitt R, Binder H, Carleton BC, Byrne J, Kaatsch P, Am Zehnhoff-Dinnesen A, Zolk O, van den Heuvel-Eibrink MM. Clemens E, et al. JMIR Res Protoc. 2019 Mar 19;8(3):e11868. doi: 10.2196/11868. JMIR Res Protoc. 2019. PMID: 30888333 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

Canadian Institutes of Health Research/Canada

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity

Affiliations

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity

Authors

Affiliations

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous